Sone-217 [upd] -

SONE-217 is an investigational drug being developed for the treatment of various types of cancer. By targeting the PD-1 protein, SONE-217 aims to enhance the body's natural immune response against cancer cells. While the potential benefits of SONE-217 are promising, further research is needed to fully understand its safety and efficacy profile.

SONE-217, also known as TAK-217 or Sonevelimab, is an investigational drug being developed by Takeda Pharmaceutical Company Limited. It is a humanized monoclonal antibody designed to target and bind to the programmed cell death-1 (PD-1) protein. SONE-217

The potential side effects of SONE-217 include: SONE-217 is an investigational drug being developed for